NeoGenomics, Inc. Stock Analysis & AI Score
NeoGenomics, Inc. (NEO) has an ST Score of 57.7 (B-), driven by its Valuation (A+) and held back by its Profitability (D+). Analysts rate it Buy with a $22.00 price target (+12.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
NeoGenomics, Inc. (NEO) has an ST Score of 57.7 (B-), driven by its Valuation (A+) and held back by its Profitability (D+). Analysts rate it Buy with a $22.00 price target (+12.5% upside).
- Strongest
- ValuationA+
- Weakest
- ProfitabilityD+
All factor grades
- ValuationA+
- MomentumA-
- GrowthB
- ForecastB
- Financial StrengthC+
- SentimentC+
- ProfitabilityD+
- Piotroski4/9
Contact
NEO stock: frequently asked questions
What is NEO's ST Score?
NeoGenomics, Inc. (NEO) has an ST Score of 57.7 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NEO a buy, hold, or sell?
Analysts rate NEO a Buy, with a price target of $22.00 (+12.5% vs the current price). Our ST Score grades it B- (57.7/100). The ST Score is a data-driven signal, not a recommendation.
What are NEO's factor grades?
Valuation A+, Profitability D+, Financial Strength C+, Momentum A-, Growth B, Forecast B, Sentiment C+.
What is NEO's valuation grade?
NeoGenomics, Inc. (NEO) earns a valuation grade of A+, measured against Medical - Diagnostics & Research peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NEO's growth grade?
NeoGenomics, Inc. (NEO) earns a growth grade of B, measured against Medical - Diagnostics & Research peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NEO's profitability grade?
NeoGenomics, Inc. (NEO) earns a profitability grade of D+, measured against Medical - Diagnostics & Research peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NEO's financial strength grade?
NeoGenomics, Inc. (NEO) earns a financial strength grade of C+, measured against Medical - Diagnostics & Research peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NEO?
The average analyst price target for NeoGenomics, Inc. (NEO) is $22.00 from 29 analysts, which is +12.5% versus the recent price of $19.56.
What is NEO's Piotroski score?
NeoGenomics, Inc. (NEO) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.